Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H27N |
Molecular Weight | 317.4672 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC1=CC=C(C=C1)C(C)(C)C)CC2=CC=CC3=CC=CC=C23
InChI
InChIKey=ABJKWBDEJIDSJZ-UHFFFAOYSA-N
InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
Molecular Formula | C23H27N |
Molecular Weight | 317.4672 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well. Butenafine hydrochloride is marketed under the trade names Mentax, Butop (India) and is the active ingredient in Lotrimin Ultra. MENTAX Cream, 1%, is indicated for the topical treatment of tinea (pityriasis)
versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. Butenafine cream 1% is indicated in treatment of tinea
pedis, tinea corporis and tinea cruris. In tinea pedis it is
recommended twice daily for 7 days or once daily for
4 weeks. In tinea cruris and tinea corporis it is recommended
once daily for two weeks.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL366 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8494375 |
|||
Target ID: CHEMBL613162 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11516941 |
|||
Target ID: CHEMBL612926 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MENTAX Approved UseMENTAX-TC Cream, 1%, is indicated for the topical treatment of tinea (pityriasis)
versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Launch Date8.4559679E11 |
|||
Sources: https://www.drugs.com/ppa/butenafine.html |
Primary | Butenafine Approved UseOTC labeling: Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm) Launch Date8.4559679E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.4 ng/mL |
6 g 1 times / day multiple, topical dose: 6 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
5 ng/mL |
20 g 1 times / day multiple, topical dose: 20 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.9 ng × h/mL |
6 g 1 times / day multiple, topical dose: 6 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
87.8 ng × h/mL |
20 g 1 times / day multiple, topical dose: 20 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35 h |
20 g 1 times / day multiple, topical dose: 20 g route of administration: Topical experiment type: MULTIPLE co-administered: |
BUTENAFINE blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 % 1 times / day multiple, topical Recommended Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: Page: CL2001-01 |
unhealthy, 2-12 n = 100 Health Status: unhealthy Condition: Tinea corporis Age Group: 2-12 Sex: M+F Population Size: 100 Sources: Page: CL2001-01 |
Sources: Page: CL2001-01 |
PubMed
Title | Date | PubMed |
---|---|---|
[Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent]. | 1991 Feb |
|
Two mechanisms of butenafine action in Candida albicans. | 1993 Apr |
|
Butenafine. | 1998 Mar |
|
Butenafine hydrochloride: for the treatment of interdigital tinea pedis. | 2000 Mar |
|
Experimental and conformational analyses of interactions between butenafine and lipids. | 2001 Dec |
|
Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis). | 2001 May |
|
A Japanese case of tinea corporis caused by Arthroderma benhamiae. | 2002 Apr |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
An unprecedented rearrangement in collision-induced mass spectrometric fragmentation of protonated benzylamines. | 2006 Sep |
|
Fungal toenail infections. | 2008 Dec 15 |
|
Are placebo-controlled trials of creams for athlete's foot still justified? | 2008 Sep |
|
Update on terbinafine with a focus on dermatophytoses. | 2009 Apr 21 |
|
Simultaneous HPLC determination of butenafine hydrochloride and betamethasone in a cream formulation. | 2009 Sep |
|
[Activity of butenafine against ocular pathogenic filamentous fungi in vitro]. | 2010 Jan |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
Patients with tinea (pityriasis) versicolor should apply MENTAX-TC Cream, 1% (Butenafine), once daily for seven days. Sufficient MENTAX-TC Cream, 1%, should be applied to cover affected areas and
extending 4 inches (10.2 cm) onto normal skin immediately surrounding the affected area.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12895182
Butenafine HCl shows minimum inhibitory concentrations ranging from 0.03–1.0 ug/mL against 30 isolates representing different dermatophyte species.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:45:41 UTC 2023
by
admin
on
Fri Dec 15 15:45:41 UTC 2023
|
Record UNII |
91Y494NL0X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007566
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
||
|
WHO-ATC |
D01AE23
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
||
|
NDF-RT |
N0000175875
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
||
|
NDF-RT |
N0000007566
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
||
|
WHO-VATC |
QD01AE23
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
101828-21-1
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
444
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
C067594
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
91Y494NL0X
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
BUTENAFINE
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
SUB06012MIG
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
DTXSID7040657
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
m2791
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | Merck Index | ||
|
6550
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
3238
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
Butenafine
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
2484
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
C72959
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
DB01091
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
47461
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000088608
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
CHEMBL990
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY | |||
|
91Y494NL0X
Created by
admin on Fri Dec 15 15:45:42 UTC 2023 , Edited by admin on Fri Dec 15 15:45:42 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |